{"code":"P04.1","type":"code","title":"Newborn affected by other maternal medication","codeAlso":[],"includes":["nonteratogenic effects of substances transmitted via placenta"],"modern_v":"official26","codeFirst":[", if applicable, withdrawal symptoms from maternal use of drugs of addiction (P96.1)","withdrawal symptoms from therapeutic use of drugs in newborn (P96.2)","any current condition in newborn, if applicable"],"excludes1":["dysmorphism due to warfarin (Q86.2)","fetal hydantoin syndrome (Q86.1)"],"excludes2":["maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0)","maternal use of drugs of addiction (P04.4-)","congenital malformations (Q00-Q99)","encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-)","neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4)","newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-)"],"isBillable":false,"fyEffectivity":{"fy2026":true,"fy2027":true,"billableFy2026":false,"billableFy2027":false},"sibling_codes":["P04.11","P04.12","P04.13","P04.14","P04.15","P04.16","P04.17","P04.18","P04.19","P04.1A"],"inclusionTerms":[],"sibling_titles":{"code":"P04.1A","title":"Newborn affected by maternal use of anxiolytics","isBillable":true},"useAdditionalCode":[],"clinicalDefinition":"Newborn affected by other maternal medication is a non-billable ICD-10-CM category code (P04.1). A more specific billable subcode must be selected for claims submission. Includes: nonteratogenic effects of substances transmitted via placenta. Excludes1 (not coded here): dysmorphism due to warfarin (Q86.2); fetal hydantoin syndrome (Q86.1). Excludes2 (not included here): maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0); maternal use of drugs of addiction (P04.","officialDefinition":"Newborn affected by other maternal medication is a non-billable ICD-10-CM category code (P04.1). A more specific billable subcode must be selected for claims submission. Includes: nonteratogenic effects of substances transmitted via placenta. Excludes1 (not coded here): dysmorphism due to warfarin (Q86.2); fetal hydantoin syndrome (Q86.1). Excludes2 (not included here): maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0); maternal use of drugs of addiction (P04.4-); congenital malformations (Q00-Q99); encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-); neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4); newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-). Code first: , if applicable, withdrawal symptoms from maternal use of drugs of addiction (P96.1); withdrawal symptoms from therapeutic use of drugs in newborn (P96.2); any current condition in newborn, if applicable.","seventhCharacterInstructions":[],"workflowProtocols":[],"guidelines":{"whenToUse":[],"whenNotToUse":[],"commonBillingMistakes":[],"codeComparisons":[],"documentationChecklist":[]},"domainLandscape":{"summary":"Primary diagnostic domain and clinical landscape evaluation.","keyCategories":[],"diagnosticContinuum":"Progression continuum from acute presentation to resolution."},"children":[],"hierarchy":[],"relatedCodes":[],"relevantCPTCodes":[],"documentationTips":[],"caseStudies":[],"description":"","overview":""}